Clinical Trial Update: Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects

View source ↗

Summary

A Phase 1 bioavailability study comparing Selegiline Transdermal System 6 mg/24 hours with EMSAM in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• EMSAM (selegiline)
• Selegiline Transdermal System (TDS) 6 mg/24 h (selegiline)

Snippet

Sponsor: Corium Innovations, Inc. | Conditions: MDD | Status: COMPLETED